Treatment
VC005 clinical trials
We’re tracking 6 recruiting studies that include VC005, each written for real people, not researchers, below.
Recruiting studies
- NCT07749716RecruitingPhase 2
Oral tablet for severe hair loss
This study tests an experimental oral tablet for severe alopecia areata, a condition that causes patches of hair to fall out. The goal is to see if it can help regrow hair safely. You may be able to join if you have this type of hair loss and meet the health requirements.
Beijing, Beijing MunicipalityAges 18–65 - NCT06723080RecruitingPhase 3
Oral VC005 for moderate to severe eczema
This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.
Nanjing, JiangsuAges 18–75 - NCT07598383RecruitingPhase 2
Gel treatment for mild-to-moderate atopic dermatitis
This study tests a new gel called VC005 to see if it safely reduces itching, redness, and irritation in people with atopic dermatitis (a chronic skin condition). You'll be randomly assigned to either the new gel or a placebo (inactive gel) and apply it to affected areas over several weeks.
Hangzhou, ZhejiangAges 18 years+ - NCT07592585RecruitingPhase 3
Testing VC005 cream for mild-to-moderate eczema in teens and adults
This study tests a new medication called VC005 to treat atopic dermatitis (eczema)—a skin condition causing itching, redness, and inflammation. Researchers want to see if VC005 can safely reduce symptoms in people aged 12 and older with mild-to-moderate cases.
Nanjing, JiangsuAges 12 years+ - NCT07172347RecruitingPhase 2
VC005 tablets for non-segmental vitiligo
This trial tests an oral tablet called VC005 to see if it can help treat non-segmental vitiligo. It may be an option for adults with vitiligo patches that are not limited to one area of the body.
Beijing, BeijngAges 18–75 - NCT07172360RecruitingPhase 3
Study of VC005 tablets for active ankylosing spondylitis
This trial tests a new tablet called VC005 to see if it helps reduce pain and stiffness in people with active ankylosing spondylitis. It's a phase 3 study, meaning it's one of the final steps before the drug may be approved for wider use.
Beijing, Beijing MunicipalityAges 18–70
What VC005 is being studied for
Conditions with recruiting VC005 studies.
Common questions
- Are there clinical trials studying VC005?
- Yes. Clin2 currently lists 6 recruiting studies that include VC005, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a VC005 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is VC005 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether VC005 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.